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Background: Previous studies by our group and others have shown that C3G interacts with Bcr-Abl through its
SH3-b domain.
Results: In this work we show that C3G and Bcr-Abl form complexes with the focal adhesion (FA) proteins CrkL,
p130Cas, Cbl and Abi1 through SH3/SH3-b interactions. The association between C3G and Bcr-Abl decreased upon
Abi1 or p130Cas knock-down in K562 cells, which suggests that Abi1 and p130Cas are essential partners in this
interaction. On the other hand, C3G, Abi1 or Cbl knock-down impaired adhesion to fibronectin, while p130Cas
silencing enhanced it. C3G, Cbl and p130Cas-SH3-b domains interact directly with common proteins involved in the
regulation of cell adhesion and migration. Immunoprecipitation and immunofluorescence studies revealed that C3G
form complexes with the FA proteins paxillin and FAK and their phosphorylated forms. Additionally, C3G, Abi1, Cbl
and p130Cas regulate the expression and phosphorylation of paxillin and FAK. p38α MAPK also participates in the
regulation of adhesion in chronic myeloid leukemia cells. It interacts with C3G, CrkL, FAK and paxillin and regulates
the expression of paxillin, CrkL and α5 integrin, as well as paxillin phosphorylation. Moreover, double knock-down
of C3G/p38α decreased adhesion to fibronectin, similarly to the single silencing of one of these genes, either C3G
or p38α. These suggest that C3G and p38α MAPK are acting through a common pathway to regulate cell adhesion
in K562 cells, as previously described for the regulation of apoptosis.
Conclusions: Our results indicate that C3G-p38αMAPK pathway regulates K562 cell adhesion through the
interaction with FA proteins and Bcr-Abl, modulating the formation of different protein complexes at FA.
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C3G is a guanine nucleotide exchange factor (GEF) for
Rap1 and R-Ras, two members of the Ras family of
small GTPases. C3G is a 140 kDa protein, build up
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reproduction in any medium, provided the orREM-CDC25-H domain, which contains the catalytic
or “GEF” domain, and a large proline-rich domain or
SH3-binding (SH3-b) domain that interacts directly
with Crk isoforms and other SH3-containing proteins
such as p130Cas, Hck and c-Abl [1-3]. C3G-mediated
Rap1 activation plays critical roles in adhesion. In fact,
C3G-Rap1 pathway is essential during early mouse em-
bryogenesis, due to its role in integrin- and paxillin-
mediated cellular adhesion and spreading [4]. Moreover,
C3G is required for the formation and stabilization of
β1-integrin and paxillin-positive FAs. C3G is also an es-
sential activator of Rap1 during cell junction formation,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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addition, C3G has been implicated in Rap1-dependent
adhesion in many hematopoietic-cell types [6,7].
We have previously identified a truncated C3G iso-
form, named p87C3G, which is abundantly expressed in
chronic myeloid leukemia (CML) cells. p87C3G interacts
with Bcr-Abl and is phosphorylated through a Bcr-Abl-
dependent mechanism [8]. Pull-down and immunopreci-
pitation studies revealed that the interaction between
p87C3G and Bcr-Abl involves the SH3-b domain
(mainly the second poly-proline stretch) of p87C3G and
the SH3 domain of Bcr-Abl. However, this interaction
is not direct, as assessed by Two-Hybrid analysis (C.
Guerrero, unpublished results). In addition, recent reports
have described an interaction between C3G and c-Abl,
which involves the C3G SH3-b domain, as demonstrated
by in vitro experiments the involvement of the C3G
SH3-b domain in this interaction [3,9]. The existence of
an interaction between C3G and Bcr-Abl through CrkL
has also been suggested, although this interaction would
involve the SH3-b domain of Abl [10,11].
It is known that Bcr-Abl induces abnormalities in the
cytoskeletal function and alters normal interactions be-
tween FA proteins and their targets, thus disturbing nor-
mal adhesion. Specifically, Bcr-Abl interacts with FA
proteins, such as p130Cas, paxillin, tensin and FAK. Bcr-
Abl induces p130Cas phosphorylation and its constitu-
tive binding to CrkL, disrupting the normal interaction
between p130Cas and tensin [12]. Additionally, Bcr-Abl is
involved in the regulation of the leukemic cells adhesion to
laminin, fibronectin and collagen through the complex for-
mation with integrin α2β1, being the Abl-SH3 domain the
responsible of these effects [13]. As a result, CML cells
have a reduced capacity to adhere to stromal layers and to
fibronectin but show increased adhesion to laminin and
collagen type IV [14,15]. This is important since altered ad-
hesion to extracellular matrix proteins could lead to pre-
mature release of CML cells from the bone marrow,
resulting in a deregulated hematopoiesis.
Recently, we have described a functional relationship be-
tween C3G and p38α MAPK in the regulation of apoptosis
in CML cells and in MEFs [16,17]. Another common issue
is that, similarly to C3G, p38MAPKs play important roles
in the regulation of cell adhesion and migration processes
[18,19]. p38 MAPK is involved in the migration of meso-
derm during the embryogenesis [20] and mediates migra-
tion of several cell types, including tumor cells [21]. p38
MAPK also regulates adhesion; cells lacking p38α showed
increased adhesion to several ECM proteins [18,22], which
correlates with increased phosphorylation of the FA pro-
teins FAK and paxillin [18]. These results indicate that
p38α negatively regulates cell adhesion.
The role of the adapter proteins CrkL, p130Cas and
Cbl in CML is well documented [1,12,23,24], and theassociation between Cbl and C3G, through CrkL, has
been described in CML cells, fibroblasts, NK cells and
T-cells [11,25-28]. Direct interaction between C3G and
p130Cas has also been reported [29]. Interestingly, all
these proteins contain SH3 and/or SH3-b domains and
participate in cellular adhesion processes, being potential
mediators of the Bcr-Abl/C3G interaction.
On the other hand, several Abl SH3 binding proteins
have been identified, such as 3BP-1 [30], Abi1 [31], Abi2
[32], AAP1 [33], RIN1 [34], and PAG [35]. Remarkably,
Abi1/2 has both, SH3 and SH3-b domains, which would
allow its simultaneous interaction with Bcr-Abl and
C3G. This arises the possibility that Abi1/2 may act as a
mediator in the C3G/Bcr-Abl interaction.
In this work we have investigated possible mediators
of the C3G-SH3-b/Bcr-Abl-SH3 domains interaction.
Considering that the SH3 domain of Abl is the one
involved in the regulation of the leukemic cells adhesive
and invasive properties, one of the hallmarks of the
pathogenesis of CML [13], and knowing the role of C3G
in cellular adhesion, we hypothesize that C3G could
modulate CML cells adhesiveness through its interaction
with Bcr-Abl at the FAs. We have also evaluated the par-
ticipation of p38α MAPK in the regulation of adhesion
in CML and its functional interaction with C3G.
Results
The Bcr-Abl SH3-domain interacts with C3G, Abi1, Cbl and
p130Cas
Previous studies by our group and others have demon-
strated the existence of functional interactions between, ei-
ther C3G and/or its isoform p87C3G, and Bcr-Abl in K562
CML cells [8,10]. The interaction between p87C3G and
Bcr-Abl involves the SH3 domain of Abl and the SH3-b
domain of C3G [8]. However, Two-Hybrid analysis indi-
cated that this binding was not direct (data not shown),
suggesting the participation of intermediates in this inter-
action. Based on that, we tried to identify potential media-
tors in the Bcr-Abl/C3G interaction among a set of
proteins involved in cell-ECM (extracellular matrix) adhe-
sion, which also participate in signaling pathways involving
C3G or Bcr-Abl. The putative candidates are CrkL,
p130Cas, Cbl and Abi1/2. To characterize these interac-
tions, we performed pull-down assays in K562 lysates using
a GST-Abl-SH3 construct as bait [8]. Figure 1A shows that
the SH3 domain of Abl interacts with Cbl, p130Cas and
p140C3G, besides the known interaction with Abi1/2 and
p87C3G [8,31,32].
Abi1-SH3/SH3-b, Cbl-SH3-b and p130Cas-SH3/SH3-b
domains interact with C3G and Bcr-Abl
To study these interactions in depth, we performed pull-
down assays, in K562 lysates, using the SH3 and SH3-b
domains of Abi1, Cbl and p130Cas fused to GST as
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Figure 1 Bcr-Abl and C3G interact with Cbl, Abi1 and p130Cas. (A) Whole cell extracts from K562 were subjected to pull-down assays using
GST-Abl-SH3 construct. The presence of C3G, Abi1, Cbl and p130Cas in the complexes was detected by inmunoblotting with specific antibodies.
Representative Western blots of pull-down assays in K562 lysates using (B) Abi1-SH3 and SH3-b domains, (C) p130Cas-SH3, P1 and P2 domains,
and (D) Cbl-SH3-b domain fused to GST as baits. The immunoblots were developed with specific antibodies against the indicated proteins.
Glutathione-sepharose beads with whole cell lysate (B + K562), lysis buffer with the corresponding GST-fused proteins (LB) and pGEX-4T-1 empty
plasmid with K562 whole cell lysate (GST) were used as negative controls. L: whole cell lysate (40 μg). The asterisks indicate unspecific bands.
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http://www.biosignaling.com/content/11/1/9baits. Both Abi1-SH3 and SH3-b domains bound to Bcr-
Abl, in agreement with the literature [31]. In addition,
both domains interacted with p87C3G and a slight inter-
action of the Abi1-SH3-b domain with p140C3G was
also detected (Figure 1B). Regarding p130Cas, Figure 1C
shows that the three tested domains (SH3-binding, P1
and P2) interact with Bcr-Abl, albeit with different af-
finities. Additionally, p130Cas-SH3 domain interacted
with p140C3G, in agreement with other studies [29],
while P1 and P2 domains associate preferentially with
p87C3G. On the other hand, Cbl-SH3-b domain clearly
interacts with both Bcr-Abl and p87C3G (Figure 1D).
Association of Cbl with Bcr-Abl, as well as with CrkL
or Grb2 (used as controls) in K562 cells has been
described previously [24], although the interaction
described by these authors involved the Bcr-Abl SH2
domain and Cbl phospho-tyrosines. The preferential
interaction of p87C3G over p140C3G with most of the
tested domains probably reflects its highest expression
in CML cells (Additional file 1) [8].These experiments support the results derived from
the Bcr-Abl-SH3 domain pull-down assays and suggest
that all these proteins form complexes. In fact, all of
them coimmunoprecipitate (Additional file 2). There-
fore, Cbl, Abi1 and p130Cas are clear candidates to act
as intermediates in the interaction between Bcr-Abl and
C3G in K562 cells. In agreement with pull-down assays,
confocal microscopy revealed a colocalization of C3G
with phospho-p130Cas, Cbl, Abi1 and Bcr-Abl (Figure 2),
which further supports that all these proteins form com-
plexes in K562 cells.
Interaction of Bcr-Abl with CrkL
CrkL, the major substrate of the tyrosine kinase Bcr-Abl,
interacts directly with Bcr-Abl through its amino ter-
minal SH3 domain and the SH3-binding region of Abl
[36,37]. Here we show that the Abl-SH3 domain also
interacts with CrkL (Additional file 3A). One possible
explanation is that CrkL, similarly to CrkII, has a puta-
tive SH3-b domain inside the SH2 domain that could
C3G-FITC p-p130Cas-Cy3 Merged DIC
C3G-FITC Cbl-Cy3
C3G-FITC Abi1-Cy3
C3G-FITC Abl-Cy3
DAPI CT
Figure 2 C3G colocalizes with phospho-p130Cas, Cbl, Abi1 and Bcr-Abl in K562 cells. Confocal microscopy images of K562 cells adhered to
fibronectin covered slides (10 μg/ml) and labeled with anti-C3G (G4, mouse monoclonal, rows 1 and 2 or 1008, rabbit polyclonal, rows 3 and 4)
and either, anti-phospho-p130Cas (rabbit polyclonal), anti-Cbl (rabbit polyclonal), anti-Abi1 (mouse monoclonal) or anti-Abl (mouse monoclonal)
specific antibodies as indicated. Anti-FITC and anti-Cy3 were used as secondary antibodies. Nuclei were labeled with DAPI. Control cells (CT) were
incubated with DAPI plus the secondary antibodies. DIC: Differential interference contrast microscopy. p-p130Cas: phospho-p130Cas. The bars
represent 10 μm.
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http://www.biosignaling.com/content/11/1/9mediate this interaction [38]. Sequence alignment
revealed that CrkL lacks the SH3-b domain present in
CrkII, although it preserves a canonical SH3-b PXXP
motif that itself is sufficient for binding to SH3 domains
[29,36] (Additional file 3B). However, the CrkL-SH2
domain does not interact with Bcr-Abl, either by
pull-down experiments (Additional file 3C) or in Two-
Hybrid analysis (Additional file 4: Method 1 and
Additional file 3D), indicating that the interaction be-
tween CrkL and Bcr-Abl, involving the Abl-SH3 do-
main, is not direct. An indirect interaction between
these two proteins independent of the Bcr-Abl pro-
line rich domain has been previously suggested [39].
Abi1 and p130Cas knock-down alter the interaction
between C3G and Bcr-Abl
To determine the contribution of these proteins to the
formation of C3G/Bcr-Abl complexes, we studied the
interaction between C3G and Bcr-Abl in K562 clones
upon silencing of Abi1, Cbl or p130Cas (Figure 3A).
Figure 3B and 3C show that Abi1 and p130Cas knock-
down clearly decreased Bcr-Abl/p140C3G interaction.
p130Cas knock-down also decreased the interaction be-
tween Bcr-Abl and p87C3G that was unaffected by Abi1
knock-down. In contrast, Cbl silencing had no effect onthese interactions (Figure 3B). On the other hand, the
interaction between CrkL and Bcr-Abl increased in Abi1
silenced cells, suggesting that CrkL and Abi1 compete
for their binding to Bcr-Abl (Figure 3B). Furthermore,
both Abi1 and Cbl silencing decreased the interaction
between Bcr-Abl and p130Cas. These results suggest
that all these proteins interact with each other and form
complexes in CML cells.
C3G, Cbl and p130Cas bind directly to common adhesion
proteins
To examine whether the interactions between the SH3
and/or SH3-b domains of the studied proteins were dir-
ect, we performed hybridizations with SH3 domain
arrays (Panomics) containing 38 SH3 domains (Array I)
and 36 SH3 domains (Array II) (Additional files 5, 6, 7
and Additional file 8: Table S1 and Additional file 9:
Table S2), using His-tagged-SH3-b domains from C3G,
Cbl and p130Cas (P2). The C3G-SH3-b domain directly
associates with the SH3 domains of LCK, SPCN, cortac-
tin, Yes1, Abl2 (ARG), SLK, c-Src, Hck, VAV-D2, Y124,
PEXD, BTK, and Stam and with less affinity to NOF2-
D1, VAV-D1, Abl and PLCγ (Additional file 5, Array I).
Results with the array II confirmed the direct binding of
C3G with c-Src and Abl2 and revealed its direct binding
Figure 3 Abi1 and p130Cas silencing alter Bcr-Abl/C3G interaction. (A) Western blot analysis of the expression of Abi1, Cbl, p130Cas and
p87C3G in whole cell lysates from K562 clones stably transfected with the indicated lentiviral shRNA particles. Relative Abi1/β-tubulin, Cbl/β-
tubulin, p130Cas/β-tubulin and C3G/β-tubulin ratios are shown. shAbi1-2, shCbl-1, shp130Cas-5, shC3G-1 and shC3G-8 were selected as
representative knock-down clones in the experiments. C: whole cell lysate of a K562 clone expressing control lentiviral shRNA. Pull-down assays
with lysates of K562 shAbi1-2, shCbl-1 and shControl (shCT) clones (B) or K562 shp130Cas-5 and shCT clones (C), using Abl-SH3 domain fused to
GST as bait. p140C3G, p87C3G, Abi1, CrkL, Cbl and p130Cas expression was detected with specific antibodies. Panels showing p140C3G and
p87C3G in Figure 3B correspond to different exposure times (longer for p140 and shorter for p87) for a better visualization of both isoforms.
Beads with lysis buffer (B), GST construct with K562 whole cell lysate (GST) and K562 whole cell lysate with lysis buffer (LB) were used as negative
controls. L: whole cell lysate (40 μg).
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http://www.biosignaling.com/content/11/1/9to NCK1-D2, OSF, Tec, PIG2, VINE-D3 and, with less
affinity, PI3α. The known binding to CRKL-D1 was con-
firmed in this experiment [40] and contrarily to what we
expected, no direct interaction with the Abi2-SH3 do-
main (AbI2B) was found. Binding to p130Cas-SH3 do-
main (BCA1) was not detected because the C3G-SH3-b
fragment used lacks the upstream sequence involved in
this interaction [29].
Similarly to the C3G-SH3-b domain, the Cbl-SH3-b
domain clearly binds to LCK, SPCN, cortactin, Yes1,
Abl2, SLK, c-Src, Hck, VAV2-D2, NOF2-D1, VAV-D1,
Y124, PEXD, BTK, Stam and Abl (array I), Abl2,
CrkL-D1, NCK1-D2, OSF, PI3α, Tec, PIG2, VINE-D3
and c-Src (array II) (Additional file 6). Interaction with
PI3kα has been reported [24]. Also, in agreement with
previous findings, a direct, although weak, interaction
between the Cbl-SH3-b domain and the CrkL-SH3(CrkL-D1) domain was observed [41], although in CML
cells Cbl interacts preferentially with the CrkL-SH2 do-
main [24]. In contrast to C3G, Cbl also interacts dir-
ectly with Itk, Dlg2, ITSN-D1 and TXK (array I) AbI2B
(Abi-2), M3KA, SNX9, VAV3-D2, and SH3-1 (SH3-con-
taining GRB2-like protein 1), being this last one in
agreement with published data [42].
The p130Cas-P2 domain (SH3-b domain-2) renders a
less specific hybridization, probably due to the smaller size
of this fragment. Similarly to C3G and Cbl, it presents a
clear direct association with LCK, Cortactin, Yes1, Abl2,
SLK, c-Src, Hck, VAV2-D2, Y124, PEXD, BTK, ITSN-D1
(array I), Abl2, NCK1-D2, OSF, PI3α, Tec, PIG2, VINE-D3
and c-Src, (array II) and it binds with less affinity to Stam,
BLK, Abl and CrkL-D1 (Additional file 7). Similarly to
Cbl, p130Cas-P2 binds with high affinity to Itk, ITSN-D1
(array I), AbI2B, SH3-1 and SNX9 and weakly to M3KA
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http://www.biosignaling.com/content/11/1/9and VAV3-D2. p130Cas-P2 presents an exclusive strong
interaction with MLPK3, PSD95, PI3-ß (array I), GRB2L-
D1, NE-DLG and NOF2-D1 (array II), and binds with less
affinity to amphiphysin, RasGAP (array I), CSKP, BIN1 and
EFS. The direct interaction between p130Cas-P2 and
CrkL-SH3 domain (CRKL-D1) contrasts with previous
reports showing a direct association between CrkL and
p130Cas through the CrkL-SH2 domain in Bcr-Abl expres-
sing cells and CML patients [12].
C3G, Cbl, Abi1 and p38α MAPK knock-down expression
inhibits K562 adhesion to fibronectin, while p130Cas
silencing increases it
We next studied the ability of K562 clones with silenced ex-
pression of C3G, p38α MAPK, Cbl, Abi1 or p130Cas to ad-
here to fibronectin, which is the optimal adhesion substrate
for K562 cells (Additional file 10), as compared to laminin
or collagen IV. C3G, Cbl, Abi1 or p38α knock-down
reduced the adhesion capacity of K562 cells while p130Cas
silencing increased it (Figure 4A). Curiously, the double
C3G and p38α MAPK knock-down did not additionally
decreased adhesion as compared to each single knock-
down (Figure 4B). This indicates that both proteins are
likely acting through a common regulatory pathway to
regulate adhesion in K562 cells.
C3G and p38α MAPK form complexes with focal adhesion
proteins
Cell adhesion to the extracellular matrix is mediated by
integrins through regulation of the formation of differentFigure 4 C3G, Cbl, Abi1, p130Cas and p38α MAPK regulate adhesion
fibronectin of K562 cells upon knock-down of C3G (shC3G-1 and shC3G-8),
of adhesion to fibronectin of K562 clones expressing interference RNAs (clo
mean ± SEM of at least three independent experiments. All values are relat
neo vector (pSuper). *p<0.05; ** p<0,01.FA complexes, being a bidirectional cross-talk between
integrins and FA proteins [43]. These complexes are con-
stituted by protein kinases, such as FAK, and scaffold pro-
teins, such as paxillin or p130Cas. In CML cells, it is
known that paxillin interacts with protein kinases such as
Src, p38 MAPK, c-Abl and FAK [44] and with Bcr-Abl
through CrkL [45]. C3G also interacts with Bcr-Abl [8]
and p130Cas [29], which agrees with data presented here.
To characterize the interactions between some of these
FA proteins and C3G or p38α MAPK in CML cells, we
performed immunoprecipitation assays in whole cell
lysates of K562 cells grown in the presence of fibronec-
tin (10 μg/ml). Results from Figure 5A show that C3G
interacts with FAK, paxillin, phospho-paxillin p68 iso-
form and p38α, apart from the already described inter-
action with CrkL (difficult to see probably due to the
competition between C3G and Bcr-Abl for the binding
to CrkL). Association of C3G with paxillin and FAK was
also supported by immunofluorescence data (Figure 5B).
Colocalization of C3G with p-Pax and p-FAK further
supports a functional relationship between C3G and
these focal adhesion proteins. p38α MAPK forms com-
plexes with paxillin, as described before [44], C3G, FAK
and CrkL. In agreement with previous studies, CrkL
interacts with C3G, Bcr-Abl and phospho-paxillin p33
isoform [15,46-48] and Abi1 interacts with c-Abl [31,32].
The interactions C3G-p38α, CrkL-FAK, FAK-p38α,
Abi1-p130Cas and CrkL-p38α have not been previously
reported, although Crk can induce p38 MAPK phos-
phorylation in some cell types [49].to fibronectin in K562 cells. (A) Percentage of adhesion to
Cbl (shCbl-1), Abi1 (Abi1-2) or p130Cas (shp130Cas-5). (B) Percentage
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Figure 5 C3G and p38α MAPK interact with FA proteins. (A) Representative immunoprecipitation assays (IP), using the indicated antibodies,
performed with protein extracts from K562 cells cultured on 10 μg/ml fibronectin for 24 h. Expression of p33, p46 and p68 phospho-paxillin
(p-Pax) and paxillin isoforms, p38α, p87C3G, CrkL, Bcr-Abl, p130Cas, Abi1 and FAK was detected by immunoblotting with specific antibodies.
GammaBind G Sepharose beads (B) with either buffer or whole cell lysate (lysate) were used as negative controls. (B) Confocal microscopy of
K562 cells adhered for 24 h to slides covered with 10 μg/ml fibronectin and labeled with the indicated antibodies. Nuclei were labeled with DAPI.
Control cells (CT) were incubated with DAPI plus the secondary antibodies. C3G-1008 (rabbit polyclonal) was used with Pax (mouse monoclonal)
and p-FAK (goat polyclonal). C3G-G4 (mouse monoclonal) was used with p-Pax (rabbit polyclonal). C3G colocalizes with p-Pax and p-FAK in a
punctuated pattern (white arrows). DIC: Differential interference contrast microscopy. Pax: paxillin. A488: Alexa Fluor 488. The bars represent 5 μm.
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http://www.biosignaling.com/content/11/1/9C3G modulates the expression and activation of focal
adhesion proteins
Next, we analyzed whether C3G overexpression
affects the expression and/or phosphorylation of
some FA proteins. Indeed, C3G overexpression led to
a clear decrease in paxillin, FAK, p130Cas and integ-
rin α5 protein levels. In contrast, an increase in
phospho-paxillin isoforms, mainly p46 and p33, was
also observed (Figure 6A). The decrease in the ex-
pression of FAK, p130Cas, integrin α5 and particu-
larly paxillin was more evident in the presence of
fibronectin (Figure 6B), indicating that an excess of
C3G downregulates the outside-in signaling by a
negative feed back mechanism. The increased levels
of phospho-paxillin could be related with this regula-
tion. Cbl protein levels slightly increased in C3G
overexpressed cells, while CrkL expression and phos-
phorylation was not affected (Figure 6A).To confirm these results through a complementary ex-
perimental approach, we analyzed the expression of
these FA proteins in K562 C3G knock-down clones.
Similarly to that observed in C3G overexpressed clones,
paxillin expression decreased in C3G knock-down cells
(Figure 6C). The decrease in paxillin expression was
confirmed by immunofluorescence confocal microscopy
of K562 cells attached to fibronectin (Figure 6D). In con-
trast, the levels of phospho-paxillin p33 and p68 iso-
forms decreased in C3G silenced clones, while they were
increased by C3G overexpression, (Figure 6C). Addition-
ally, a decrease in Cbl protein levels and a slight de-
crease in phospho-CrkL were also observed in the C3G
knock-down clones, while no significant changes in
p130Cas and CrkL levels were observed (Figure 6C).
Fibronectin partially reversed the effect of C3G silencing
on paxillin expression and phosphorylation, in contrast
to the effect of fibronectin in C3G overexpressing
Figure 6 C3G modulates the expression and activation of FA proteins. (A) Western blot analysis of whole cell lysates (50 μg of protein) from
K562 cells stably transfected with pLTR2C3G or the empty pLTR2 vector grown in suspension for 24 h. Paxillin (Pax), Cbl, CrkL, FAK, p130Cas and
integrin α5 (Int α5) expression and paxillin and CrkL phosphorylation were detected with specific antibodies (B) Comparative analysis of the
expression of Int α5, FAK, Pax and p130Cas in the above K562 clones grown with 10 μg/ml fibronectin (FN) for 24 h or in suspension (Susp). β-actin
and β-tubulin (ß-Tub) levels were used as loading controls. (C) Western blot analysis of whole cell lysates from K562 cells stably transfected with
shC3G (clone 1) or shCT lentivirus, either grown with fibronectin (FN) or in suspension (Susp) for 24 h. FAK, Cbl, paxillin, p130Cas and CrkL
expression and paxillin, p130Cas and CrkL phosphorylation were detected. Relative ratios between the levels of these proteins and ß-tubulin are
shown. (D) Paxillin expression is decreased in C3G silenced cells. Confocal microscopy of control (shCT) and shC3G-1 K562 cells adhered to
fibronectin and labeled with anti-paxillin-Cy3 and anti-phalloidin antibodies. Nuclei were labeled with DAPI. Control cells (CT) were incubated with
DAPI plus the secondary antibodies. The bars represent 10 μm (rows 1 and 3) and 7.5 μm (rows 2 and 4). (E) Immunoprecipitation assays (IP) of
K562 cell lysates expressing, either shC3G or shCT, with the indicated antibodies followed by Western blot analysis of CrkL, Paxillin, p130Cas and Bcr
expression. GammaBind G Sepharose beads (B) with either buffer or whole cell lysate (lysate) were used as negative controls. L: total cell lysate, Pax:
paxillin, pY: phospho-tyrosine.
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C3G in the regulation of the outside-in pathway trig-
gered by fibronectin.
We next analyzed the effect of C3G knock-down on
FA proteins interactions by immunoprecipitation assays
performed in control (shCT) and C3G knock-down
K562 cells grown on fibronectin. Remarkably, C3G silen-
cing produced a decrease in the association between
CrkL and Bcr-Abl, while it promoted the CrkL-paxillin
interaction (marked by arrows) characteristic of tumoral
cells (Figure 6E).
Collectively, our data suggest that C3G plays a role
in the regulation of the expression of FA proteins,
and in their activation and association dynamics.
Similarly to our previous published data on apoptosis,
C3G seems to play a dual role in the regulation of cell
adhesion, as both upregulation and downregulation of
C3G expression have similar effect on the expression
of proteins involved in the signaling pathways regulat-
ing cell adhesion.
p38α MAPK regulates FA protein expression and
activation in a C3G antagonistic fashion
Next, we wanted to analyze whether p38α MAPK plays
a role in the regulation of the expression and activation
of FA proteins. Figure 7A-B shows that p38α knock-
down led to an upregulation of paxillin, integrin α5 and
CrkL expression, especially in the presence of fibronec-
tin, while FAK and p130Cas protein levels remained un-
changed. C3G expression was also increased in p38α
silenced cells (Figure 7C). In addition, p38α silencing
induced an increase in the phosphorylation of all paxillin
isoforms, which was more notorious in the presence of
fibronectin. Similar results were obtained when cells
were grown in the presence of SB203580 for 48 h, which
even reinforced the effect of p38α silencing (7D). These
results support an inhibitory effect of p38α on the ex-
pression and activation of FA proteins, in agreement
with previous reports [18].
Cbl, Abi1 and p130Cas regulate the expression and
activation of FAK and paxillin in K562 cells
Finally, we have analyzed the contribution of adhesion
proteins that interact with C3G and Bcr-Abl, such as
Cbl, Abi1 and p130Cas, to the regulation of the expres-
sion and phosphorylation of FAK, p130Cas and paxillin,
by knocking down these genes. The greatest effect was
observed in Abi1 silenced cells maintained in suspen-
sion, where the protein levels of p130Cas, FAK and pax-
illin, as well as paxillin phosphorylation, decreased
(Figure 8). These results are in agreement with the
observed decrease in adhesion to fibronectin of Abi1
knock-down clones. This effect was reverted in the pres-
ence of fibronectin, where FAK expression was evenincreased, indicating that the expression of all these pro-
teins is regulated by the fibronectin-triggered pathway.
On the other hand, p130Cas knock-down led to an in-
crease in the phosphorylation of paxillin, and to a slight
decrease in FAK protein levels. In contrast, Cbl knock-
down seems to have the opposite effect to that of
p130Cas knock-down, as it reduces FAK levels and
increases paxillin phosphorylation. In summary, these
results are compatible with a negative role of p130Cas in
CML cell adhesion and a positive role of Cbl, in agree-
ment with the adhesion behavior to fibronectin of the
respective silenced clones.
Discussion
In this paper we have explored the nature of the inter-
action between C3G and Bcr-Abl proteins. This inter-
action requires Abi1 and p130Cas, while Cbl seems not
to contribute, albeit it forms complexes with C3G. In
this regard, a connection between c-Cbl and the regula-
tion of cell migration and spreading through CrkL-C3G-
Rap1 and Rac has been described [50]. Likewise, the
interaction between Bcr-Abl and p130Cas seems to be
more stable in the presence of Abi1 and Cbl. In contrast,
CrkL competes with Abi1 in its binding to the SH3 do-
main of Abl.
The Abl-SH3 domain interacts with C3G and Abi1, as
previously published [3,8,9]. In addition, we have uncov-
ered a novel interaction between the Abl-SH3 domain
and the Cbl-SH3-b domain. This has been demonstrated
by i) pull-down assays and ii) far western analysis using
arrays of purified SH3 domains, which indicate that this
interaction is direct. A direct interaction between Cbl
and the Abl-related protein Arg was also detected. Add-
itionally, the Cbl-SH3-b domain can also establish an in-
direct interaction with Bcr-Abl, which involves Abl-Y177
and Grb2 [24]. Therefore, we describe a novel direct
interaction, between Cbl and Bcr-Abl through their
SH3-b and SH3 domains respectively, in addition to the
direct Bcr-Abl-Cbl interaction, involving the Abl SH2
domain and Cbl phospho-tyrosines [24,51].
A direct association between p130Cas and the SH2
domains of Bcr-Abl or CrkL has been previously
described [12]. Here we show that interactions involving
the Bcr-Abl SH3 domain and the SH3 or SH3-b
domains of p130Cas are also produced in CML cells.
Moreover, the association between the p130Cas SH3-b
and the Abl-SH3 domains could be direct, based on far
Western experiments. Our results also illustrate a non-
canonical association between p130Cas and p87C3G,
which involves the proline-rich domain of p130Cas but
not its SH3 domain. In this line, recent reports have
assigned important roles to p130Cas SH3 and SH3-b
domains in FA formation and sustained FA disassem-
bling, respectively [52,53]. It is likely that the interaction
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Figure 7 p38α MAPK downregulate the expression and phosphorylation of FA proteins. (A) Representative Western blots showing the
expression and phosphorylation (p) of FAK, p130Cas, paxillin (Pax), CrkL, p38α and integrin α5 (Int α5) in K562 clones expressing pSuper-p38α
MAPK (p38αi) or the empty vector (pSuper). Cells were cultured in suspension (Susp) or attached to fibronectin (FN). Relative ratios between the
levels of the different analyzed proteins and ß-tubulin are shown. (B) The histogram represents the quantification by densitometry of the Western
blot bands for each protein, relative to ß-tubulin. Susp: suspension; FN: fibronectin. (C) Western blot showing the expression of p140C3G in K562
cells expressing pSuper-p38α MAPK (p38αi) or empty vector (pSuper) grown on suspension. (D) Representative Western blots showing the
expression and phosphorylation (p) of paxillin (Pax), CrkL, p38α and integrinα5 (Int α5) in K562 cells expressing pSuper-p38α MAPK (p38αi) or
empty vector (pSuper) grown on suspension and treated or not with 5 μM SB203580 (SB) for 48 h. Relative ratios between the levels of the
different analyzed proteins and ß-tubulin or ß-actin are shown.
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tions with FA molecules, thus, contributing to the adhe-
sion defects observed in CML cells [15].
In addition, we have uncovered the existence of a series
of new interactions, not described previously, between
C3G, Bcr-Abl and FA proteins, such as Cbl, p130Cas, Abi1
and CrkL: (i) interaction between p87C3G and Abi1 SH3
or SH3-b domains; (ii) interaction of Cbl SH3-b domain
with p87C3G; (iii) interaction between Bcr-Abl SH3 do-
main and CrkL. All these novel interactions strongly sug-
gest the existence of complex networks between these
proteins with dynamic connections involving multiple dif-
ferent domains. This reflects the complexity and plasticity
of the regulation of the FA contacts in CML cells.Figure 8 Abi1, Cbl and p130Cas contribute to FA regulation. (A) Repre
(p) of the indicated proteins in K562 cells upon knock-down of Cbl (clone
cells (see Figure 3). ß-actin was used as loading control. Relative ratios betw
shown. (B) The histograms represent the relative values of the levels of exp
shRNA from Santa Cruz Biotech., shCT-sg: Control shRNA from Sigma. SuspDifferent from our results derived from Two-Hybrid
assays (unpublished data), SH3 arrays hybridization
showed a weak interaction between C3G-SH3-b and
Abl-SH3 domain (lower than the positive controls). This
weak interaction detected in vitro may be not strong
enough to be detected in vivo.
It is noteworthy that the SH3-b domains of C3G, Cbl
and p130Cas show similar hybridization patterns with
the SH3 domain arrays, which suggests that these three
proteins are involved in the regulation of common sig-
naling pathways. In fact, C3G, p130Cas and Cbl directly
interact with proteins involved in FAs dynamics, in
agreement with its participation in these complexes.
Among them, we find Cortactin and Vinexin (VINE),sentative Western blots showing the expression and phosphorylation
1), Abi1 (clone 2) or p130Cas (clone 5), and their corresponding control
een the levels of the different analyzed proteins and ß-actin are
ression of the analyzed proteins relative to ß-tubulin. shCT-sc: Control
: suspension; FN: fibronectin.
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adapter proteins such as CrkL. Immunoprecipitation
assays confirmed previously described interactions be-
tween p-Paxillin and CrkL or p38α MAPK [44,45] and
of CrkL with Bcr-Abl [46]. In addition, we also found a
strong interaction between Abi1 and p130Cas, FAK and
p38α MAPK and an interaction of p38α MAPK with
C3G or CrkL. To our knowledge, these interactions have
not been described so far.
In agreement with previous results [4,54], our data
suggest that C3G plays a key role in the regulation of
CML cell adhesion as (i) C3G silencing decreases adhe-
sion to fibronectin, (ii) changes in C3G expression alters
the levels of expression and activation of FA proteins,
such as FAK, paxillin, CrkL, Cbl and integrin α5, and
(iii) C3G silencing increases the interaction between
CrkL and paxillin (difficult to observe in control cells)
and decreases CrkL interaction with Bcr-Abl. This is
relevant, since aberrant interaction between CrkL and
paxillin is induced by Bcr-Abl in CML cells [46]. There-
fore, p140C3G could act as a negative regulator of Bcr-
Abl-induced abnormal adhesion. A role for C3G in the
formation or stabilization of integrin β1- and paxillin-
positive FAs has also been described in MEFs [54].
In agreement with other studies [55], Abi1 is a positive
regulator of adhesion to fibronectin. In contrast, our
results on Cbl are different from previous reports. Cbl
negatively regulates cell adhesion in most systems by tar-
geting α5-integrin, CrkL and FAK for ubiquitination
[56,57]. However, our results reveal a positive role for
Cbl in CML cell adhesion, as Cbl silencing impaired ad-
hesion of CML cells. p130Cas seems to exert a negative
effect in CML adhesion, in agreement with its role in
migration and invasion [58,59]. Regarding p38α we have
contradictory results as p38α knock-down decreased ad-
hesion to fibronectin, but also increased the levels and/
or activity of some FA proteins such as paxillin. The
decreased adhesion observed in p38α silenced K562 cells
point out to a positive regulation of CML adhesion by
p38α, according to the role proposed for p38 in adhesion
in human melanoma cells [60] and in Karpas 299 lymph-
oma cells based on the effect of the p38α/ß inhibitor
SB203580 [61]. However, results derived from studies
performed with p38α knock-out cells indicates that p38α
plays a negative role in adhesion in mouse embryonic
stem cells [18] and in embryonic cardiomyocytes [62].
Differences between cell types might account for these
distinct functions of p38α in adhesion. It would be also
possible that p38 could play a different role in normal
and tumoral cells as adhesion is altered in tumoral cells.
In contrast to the reduced adhesion found in p38α
silenced K562 cells, either p38α knockdown or SB203580
treatment induced an increase in the expression of FA
proteins, mainly paxillin, integrin α5 and CrkL, as well asan increase in phospho-paxillin, which is normally asso-
ciated with increased adhesion. This effect was stronger
in cells attached to fibronectin. Similar results were
observed by Guo and coworkers [18]. A plausible explan-
ation is that the increase in the expression of FA proteins
induced by p38α silencing alters the stoichiometry of the
FA complexes, leading to adhesion defects likely due to
the impairment of assembly and disassembly of focal ad-
hesion complexes. Additionally, it should be noted that
adhesion experiments were performed under serum-
deprivation, which induces the activation of p38α and
other p38 isoforms (mainly ß) [62,63] and can alter the
activity of other signaling molecules involved in adhesion
such as Rac1 [62]. All this would lead to a potential im-
balance of different signaling pathways that could induce
a decrease in adhesion. Finally, the fact that double C3G/
p38α silenced cells present a similar decreased adhe-
sion to fibronectin that the single knock-down clones,
suggests that both proteins could participate in the
same signaling pathway regulating cell adhesion. This
is supported by the immunoprecipitation studies show-
ing interaction between C3G and p38α MAPK. In
addition, C3G and p38α MAPK interact with paxillin
and FAK, indicating that they form complexes at the
FA. Especially relevant is the interaction between p38α,
paxillin and FAK, which strongly indicate that p38α
stably interacts with these proteins.
The pathogenesis of CML is caused in part by disor-
ders in the motility of CML cells as well as in their ad-
herence to fibronectin and other substrates [15]. It has
been suggested that Bcr-Abl interferes with the signaling
normally induced by ß1 integrin activation, leading to a
decrease in adhesion to fibronectin [14,64]. In fact, Bcr-
Abl mimics integrin activation to establish aberrant
interactions with paxillin [45]. There are evidences about
the involvement of the SH3 domain of Bcr-Abl in the
regulation of adhesion of leukemic cells through the for-
mation of complexes with α2β1 integrin [13]. Moreover,
interaction of Abi1/2 with the Bcr-Abl SH3 domain
negatively regulates its kinase activity [31,32,65]. In fact,
Abi1 triggers a downstream pathway, involving WAVE2
that contributes to Bcr-Abl-induced abnormalities in the
cytoskeletal and integrin function [55]. Results presented
herein suggest that Bcr-Abl function and consequently
CML cell adhesion, could also be regulated by C3G, Cbl,
p130Cas, CrkL and p38α MAPK through interactions
involving the SH3 domain of Bcr-Abl. Supporting this
idea, silencing of Abi1, C3G, Cbl, p130Cas and p38α
regulate the expression and/or activation of FA proteins
in CML cells. Moreover, p140C3G silencing decreases
the Bcr-Abl/CrkL association and reinforces the abnor-
mal interaction between CrkL and paxillin induced by
Bcr-Abl, indicating that p140C3G negatively regulates
the defective adhesion induced by Bcr-Abl.
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Our data indicate that C3G plays a relevant role in
the regulation of adhesion in CML cells by interacting
with Bcr-Abl, p38αMAPK, Cbl, p130Cas, Abi1, FAK
and paxillin at the focal adhesions. It is likely that
p140C3G levels in CML cells might be tightly con-
trolled, as either its overexpression or downregulation
induce a decrease in the protein levels of key FA pro-
teins, such as paxillin and FAK. A similar behavior
was observed in the regulation of apoptosis in CML
cells [16]. In this line, it is plausible to hypothesize
that the C3G isoform, p87C3G, participates in the
perturbation of the adhesive properties of the CML
cells through interaction with the Bcr-Abl-SH3 do-
main (regulator of the adhesion) and the establish-
ment of aberrant associations with FA proteins, thus
avoiding their normal interaction with other proteins,
including p140C3G. Further investigation is warranted
to ascertain the relationship between p140C3G and
p87C3G in the regulation of CML adhesion.
Our data also support a role for p38α in cell adhe-
sion in CML as p38α knock-down decreases adhesion
to fibronectin and changes the levels and/or phos-
phorylation state of some FA proteins. In addition,
because silencing of either p38α and/or C3G induced
a similar reduction in adhesion, p38α might be acting
in the C3G pathway. Future studies will uncover the
precise function of p140C3G, p87C3G and p38α in
the regulation of all the different proteins involved in
adhesion.
Materials and methods
Cell lines and expression constructs
K562 (ATCC, CCL243), a human cell line derived from a
patient with CML in terminal blast crisis, was maintained
in RPMI 1640 containing 10% fetal bovine serum (FBS).
C3G overexpressing construct, pLTR2C3G, and constructs
containing shRNAs to target either human C3G or p38α
genes using pSuper.neo+gfp vector (Oligoengine) have
been described previously [16,66].
K562 infection with shRNA lentiviral particles
Expression of C3G, Abi1 and Cbl was silenced in K562
cells by transfection of (h) Lentiviral Particles: C3G
shRNA (sc-29863-V), Abi1 shRNA (sc-40306-V), Cbl
shRNA (sc-29242-V) and control shRNA (sc-108080)
from Santa Cruz Biotechnology, following the manufac-
turer`s protocol. For p130Cas silencing we used p130Cas
shRNA (MISSIONW Transduction particles NM_014567)
and control shRNA (MISSIONW pLKO.1-puro Empty
Vector Control Transduction Particles) from Sigma.
Puromycin-resistant clones were selected after 15 days
in culture in 10%FBS/RPMI media supplemented with
2 μg/ml puromycin.Antibodies
Antibodies against: C3G (C-19, G4 and H-300), CrkL
(C-20), Bcr (G6), c-Abl (2411)–, Cbl (C-15), Abi1
(H-80), p130Cas (35B.1A4), Grb2 (C-23), GST (B-14),
p38α (C-20) and integrin α5 (H-104), p-FAK (ser 722)
were from Santa Cruz Biotechnology; β-Tubulin clone
2-28-33 and Actin, clone MM2/193 were from Sigma-
Aldrich; FAK, phospho-p130Cas (Tyr249) and
phospho-CrkL (Tyr207) were from Cell Signaling
Technology; paxillin (clone 349) was from BD Bios-
ciences; phospho-paxillin (Y118) was purchased from
Life Technologies. Anti-His6-Peroxidase was from
Roche. Anti-Abi1 antibody (SSH3BP1) is a monoclonal
antibody from Abcam (#ab11222). C3G-1008 serum
[66] was used in the immunofluorescence experiments.
As secondary antibodies we used: Cy3 anti-rabbit, Cy3
anti-mouse, Cy5 anti-rabbit, Alexa Fluor 488 anti-goat,
FITC anti-rabbit, and FITC anti-mouse from Jackson
ImmunoResearch Laboratories, Inc. For F-actin detec-
tion we used Oregon GreenW 514 phalloidin from Life
Technologies.
Cell adhesion assay
Adhesion of K562 cells infected with shRNA lentivirus
(knock-down) was performed as described [67]. Briefly, 96-
well plates were coated with fibronectin at 50 μg/ml in PBS
and then blocked by the addition of BSA 1%. Cells were
washed with PBS and resuspended in medium without
serum at 5×106cells/ml. Then, cells were labeled with Cal-
cein AM fluorescence dye (BD Biosciences) according to
manufacturer`s instructions and added to each microplate
well in 100 μl at 5×106 cells/ml. After 3 h at 37°C, plates
were washed 3 times with medium and inverted onto filter
paper to blot excess liquid. The remaining calcein-labeled
cells were suspended in PBS and used to determine the
total of cells added. Adhesion was measured in a fluores-
cence plate reader (ULTRA Evolution; Serial number:
12903200010; Firmware: E 1.03 02/03 EVOLUTION;
XFLUOR4 Version: V 4.50). The percentage of adhesion
was determined by dividing the corrected (background sub-
tracted) fluorescence of adherent cells by the total corrected
fluorescence of cells added to each microplate well.
Immunoblotting
Whole cell lysates were prepared using cell lysis buffer
(20 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% Triton
X-100 (or NP-40), 0.1% Na deoxycholate, 0.1% SDS)
supplemented with 1 mM PMSF, 10 μg/ml Aprotinin
and 10 μg/ml Leupeptin. Cell debris was removed by
spinning at 10000 g for 10 min at 4°C.
Immunoprecipitation
Immunoprecipitation was performed as described [68].
Prior to the immunoprecipitation, lysates were precleared
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beads (GE Healthcare Life Sciences) for 30 minutes.
Pull-down assays
Constructs: Abi1-SH3, Abi1-SH3-b (SH3-binding), Cbl-
SH3-b and p130Cas-SH3, p130Cas-P1 (proline-rich do-
main 1 or SH3-b1) and p130Cas-P2 (SH3-b2) domains
were expressed as GST-fusion proteins. To do so, frag-
ments were amplified by PCR and cloned into EcoRI-
XhoI sites of pGEX-4T-1 (GE Healthcare Life Sciences).
The oligos used were Abi1SH3-F: 5´-GGGGAATTCC
CCAAGAATTATATTGAGAAAGTT-3´ and Abi1SH3-R:
5´-GGGCTCGAGTTAATCAGTATAGTGCATGATTGA-
3; Abi1SH3b-F: 5´-GGGGAATTCCCCATTGCTGTGCC
TACA-3´ and Abi1SH3b-R: 5´-GGGCTCGAGCAGCCT
CCTCATCTTCAT-3´; CblSH3b-F: 5´-GAGGAATTCCC
GCCTTCTCCATTCTCC-3´ and CblSH3b-R: 5´-GGGCT
CGAGAGGTGGCAGTTTTGGCAC-3´; p130CasSH3-F:
5´-AGGGAATTCAACCACCTGAACGTGCTG-3´ and
p130CasSH3-R: 5´-AGGCTCGAGGCCCACCAAGAT
CTTGAG-3; p130CasP1-F: 5´-AGGGAATTCGATAA
GAAGCCAGCAGGG-3 and p130CasP1-R: 5´-AGG
CTCGAGGTAGACGCTGTCTGGCTG-3´; p130CasP2-F:
5´-AGGGAATTCTCACTGCTCTTCAGACGG-3´ and
p130CasP2-R: 5´-GGGCTCGAGGGTGAACTTAGGG
GGTGA-3´. GST-Abl-SH3 and GST-C3G-SH3-b con-
structs have been described previously [8].
Pull-downs were carried out by incubating 1 mg of
protein extract in lysis buffer with 12 –μg of GST-fusion
proteins, bound to glutathione-sepharose 4 fast flow
beads (GE Healthcare Life Sciences), for 2 hours at 4°C.
Complexes were subjected to 3 washes in lysis buffer
and boiled in loading buffer before SDS- PAGE.
Immunofluorescence
Immunofluorescence was performed essentially as
described [68].
SH3 domain arrays
Panomics´ SH3 domain Arrays are designed to determine
whether a protein of interest binds to multiple SH3
domains (Panomics). Recombinant proteins of interest
(C3G-SH3-b, Cbl-SH3-b or p130Cas-SH3-b domains) were
engineered with a N-Terminal His-Tag by cloning the cor-
responding fragments into the pET15b-derived plasmids
(Novagen-EMD Millipore) pETEV15b [69] and pET15b-
NBKSXa (Additional file 11: Methods 2 and Additional file
12: Method 3). Proteins were expressed in E. coli strain
BL21 (DE3) and purified by affinity chromatography as
described [70]. Purified proteins were hybridized with the
SH3 Domain Array I (Panomics, Cat #MA3010), and Array
II (Panomics, Cat #MA3011), following the manufacturer`s
protocol. Hybridizations were visualized with peroxidase-
conjugated anti-His antibodies, followed by ECL plus(Amersham). Spots with intensities similar or stronger than
positive controls (pos) were selected as ligands of the cor-
responding SH3-b domain.
Image processing
Quantification of band intensity was performed by Image
J version 1.24 software [71].
Statistical analysis
Data are represented as mean ± SEM. Statistical analysis
was performed using an unpaired Student's t-test. Results
were considered significant when p<0.05(?).
Additional files
Additional file 1: Comparative expression of C3G isoforms
p140C3G and p87C3G in whole cell lysates from NIH 3T3, Boff210
and K562 cells. Boff210 are BaF/3-derived cells expressing the Bcr-Abl
oncogene [8].
Additional file 2: C3G forms immunocomplexes with Bcr-Abl,
p130Cas, Cbl and Abi1. Immunoprecipitates of K562 lysates with the
indicated antibodies. Immunoblotted proteins are indicated on the margin.
Antibodies used in the immunoprecipitations and immunoblotting are
described in the manuscript. IP: immunoprecipitation; IB: immunoblotting;
B: γ-bind sepharose beads; L: whole cell lysate.
Additional file 3: Abl-SH3 domain interacts with CrkL by an indirect
mechanism. (A) Detection of CrkL by pull-down assay in K562 lysates,
using the Abl-SH3 domain fused to GST as bait. (B) CrkII and CrkL SH2-
domain sequence alignment. The internal SH3-b domain within the CrkII
SH2 domain is overlined with a double arrow. The putative proline-rich
motifs are shadowed. (C) Pull-down assays in K562 lysates using the CrkL
SH2 or SH3-N domains fused to GST as baits. Expression of Bcr-Abl,
p140C3G and p87C3G was detected by immunoblotting with antibodies
against Bcr and C3G (C-19) respectively. (D) Two-Hybrid analysis of whole
CrkL, CrkL-SH2 or CrkL-SH3-N domains, cloned into pSos, and Abl-SH3
domain cloned in pMyr. PD: pull-down. L: whole cell lysate.
Additional file 4: Method 1. Two-Hybrid. To detect direct interactions
between CrkL-SH2 and Bcr-Abl-SH3 domains we used the Two-Hybrid
System CytoTrapW Vector Kit (Agilent Technologies, formerly Stratagene)
following the manufacturer`s indications. CrkL-SH2 domain was amplified
with oligos CrkL-F: 5’-TTTGGATCCATGTCCTCCGCCAGGTT-3 and CrkL SH2-
R: 5’-TTTGAATTCTCATGGGTGCTGAGACAGATC-3’; CrkL-SH3-N domain was
amplified with oligos CrkL-SH3-F: 5’-AAAGGA TCCGATCTGTCTCAGCAC
CCA-3’ and CrkL-SH3-R: 5’-TTTGAATTCTCAAGCAGGTTCTGGGATCC-3’.
Whole CrkL c-DNA was amplified with oligos CrkL-F (see above) and
CrkL-R: 5’-TTTGAATTCTCACTCGTTTTCATCTGGGT-3’. All CrkL fragments
were cloned into pSos plasmid. Abl-SH3 domain was amplified with
oligos Abl-SH3-F: 5´-CCCGAATTCTTTCTGAATGTCATCGTCC-3´ and Abl-SH3-
R: 5´-CCCCTCGAGAGAAGCTGCCATTGATCC-3´ and cloned into pMyr plasmid.
Additional file 5: Western blots of arrays I and II hybridized with
His-tagged-C3G-SH3-b domain and developed with anti-His
antibodies. Each pair of dots represent an immobilized SH3 domain
fused to GST (see details in Materials and Methods). Dots labeled as (pos)
are histidine ligands which are used as positive controls for the
hybridization and detection. GST dots are the negative controls.
Additional file 6: Western blots of arrays I and II hybridized with
His-tagged-Cbl-SH3-b domain and developed with anti-His
antibodies. Each pair of dots represent an immobilized SH3 domain
fused to GST (see details in Materials and Methods). Dots labeled as (pos)
are histidine ligands which are used as positive controls for the
hybridization and detection. GST dots are the negative controls.
Additional file 7: Western blots of arrays I and II hybridized with
His-tagged-p130Cas-P2 domain and developed with anti-His
antibodies. Each pair of dots represent an immobilized SH3 domain
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are histidine ligands which are used as positive controls for the
hybridization and detection. GST dots are the negative controls.
Additional file 8: Table S1. SH3 domain list Array I.
Additional file 9: Table S2. SH3 domain list Array II.
Additional file 10: Histogram representing the percentage of cell
adhesion to laminin, fibronectin or collagen of K562 clones stably
transfected with lentiviral particles to silence C3G expression
(shC3G-1) or with shRNA control (shCT). *p<0.05 versus shCT.
Additional file 11: Method 2. pET15b-NBKSXa vector cloning region.
pET15b-NBKSXa cloning/expression region (modified from pET15b)
indicating the histidine tag and the thrombin recognition sequence and
cleavage site.
Additional file 12: Method 3. Cloning of C3G-SH3-b, Cbl-SH3-b or
p130Cas-SH3-b domains into pETEV15b or pET15b-NBKSXa vectors. C3G-
SH3-b domain was amplified by PCR with oligos C3GSH3-bF: 5´-
GGGGAATTCCCATGGCTGGCATTCGGGTGGTTGAT-3´ and C3GSH3-bR: 5´-
CCCGGATCCCTACTAACTGCCGTCTCTGCTGTCC-3´ and cloned into NcoI-
BamHI sites of pETEV15b. Cbl-SH3-b domain was amplified with oligos
CblSH3bBamHI-F:5´-GGGGGATCCCCGCCTTCTCCATTCTC-3´ and
CblSH3bXhoI-R: 5´-CCCCTCGAGCTACTAAGGTGGCAGTTTTGGCAC-3´ and
cloned into pET15b-NBKSXa by BamHI-XhoI digestion. p130CasP2-domain
(proline-rich region 2) was amplified with oligos CasP2BamHI-F: 5´-
AGGGGATCCTCACTGCTCTTCAGACGG-3 and CasP2XhoI-R: 5´-
GGGCTCGAGCTACTAGGTGAACTTAGGGGGTGA-3´ and cloned into BamHI-
XhoI sites of pET15b-NBKSXa.
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